Hepatitis B and C in pregnancy: a review and recommendations for care
Our objective was to provide a comprehensive review of the current knowledge regarding pregnancy and hepatitis B virus (HBV) or hepatitis C virus (HCV) infection as well as recent efforts to reduce the rate of mother-to-child transmission (MTCT). Maternal infection with either HBV or HCV has been li...
Gespeichert in:
| Veröffentlicht in: | Journal of perinatology 2014-12, Vol.34 (12), p.882-891 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 891 |
|---|---|
| container_issue | 12 |
| container_start_page | 882 |
| container_title | Journal of perinatology |
| container_volume | 34 |
| creator | Dunkelberg, J C Berkley, E M F Thiel, K W Leslie, K K |
| description | Our objective was to provide a comprehensive review of the current knowledge regarding pregnancy and hepatitis B virus (HBV) or hepatitis C virus (HCV) infection as well as recent efforts to reduce the rate of mother-to-child transmission (MTCT). Maternal infection with either HBV or HCV has been linked to adverse pregnancy and birth outcomes, including MTCT. MTCT for HBV has been reduced to approximately 5% overall in countries including the US that have instituted postpartum neonatal HBV vaccination and immunoprophylaxis with hepatitis B immune globulin. However, the rate of transmission of HBV to newborns is nearly 30% when maternal HBV levels are greater than 200 000 IU ml
−1
(>6 log
10
copies ml
−1
). For these patients, new guidelines from the European Association for the Study of the Liver (EASL) and the Asian Pacific Association for the Study of the Liver (APASL) indicate that, in addition to neonatal vaccination and immunoprophylaxis, treating with antiviral agents such as tenofovir disoproxil fumarate or telbivudine during pregnancy beginning at 32 weeks of gestation is safe and effective in preventing MTCT. In contrast to HBV, no therapeutic agents are yet available or recommended to further decrease the risk of MTCT of HCV, which remains 3 to 10%. HCV MTCT can be minimized by avoiding fetal scalp electrodes and birth trauma whenever possible. Young women with HCV should be referred for treatment post delivery, and neonates should be closely followed to rule out infection. New, better-tolerated treatment regimens for HCV are now available, which should improve outcomes for all infected individuals. |
| doi_str_mv | 10.1038/jp.2014.167 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4777346</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A392572457</galeid><sourcerecordid>A392572457</sourcerecordid><originalsourceid>FETCH-LOGICAL-c774t-e385174d14980a25ac9d0b1f2435c24993640f2ae85c85cf3d88fd7cfa34dacd3</originalsourceid><addsrcrecordid>eNqNkt1rFDEUxQdR7Fp98l0GBBF01nxNPvog1KVaoeCLPoc0c2c3y0wyJjOV_vdmurXuSpGSgcCc3z3hnnuL4iVGS4yo_LAdlgRhtsRcPCoWmAle1TWjj4sFEoxWkjJ-VDxLaYvQLIqnxRGpCaVY1Yvi7BwGM7rRpfJTaXxTrkrnyyHC2htvr09KU0a4cvDrRoxgQ9-Db3JJ8KlsQyytifC8eNKaLsGL2_u4-PH57PvqvLr49uXr6vSiskKwsQIqayxYg5mSyJDaWNWgS9wSRmtLmFKUM9QSA7K2-WtpI2XbCNsayhpjG3pcfNz5DtNlD40FP0bT6SG63sRrHYzTh4p3G70OV5oJIXIO2eDtrUEMPydIo-5dstB1xkOYks4ZEqQ4F_gBKJeEI8nkA1AiCcOS0oy-_gfdhin6HJomuXlOFeP4f1T2ElwpjMRfam060M63Ifds56f1KVWkFoTVM7W8h8qngd7Z4KF1-f9BwZu9gg2Ybtyk0E03Iz8E3-1AG0NKEdq7QWCk59XU20HPqznHmulX-7O7Y__sYgbe74CUJb-GuNf0PX6_ATCW6AA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1627699107</pqid></control><display><type>article</type><title>Hepatitis B and C in pregnancy: a review and recommendations for care</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Dunkelberg, J C ; Berkley, E M F ; Thiel, K W ; Leslie, K K</creator><creatorcontrib>Dunkelberg, J C ; Berkley, E M F ; Thiel, K W ; Leslie, K K</creatorcontrib><description>Our objective was to provide a comprehensive review of the current knowledge regarding pregnancy and hepatitis B virus (HBV) or hepatitis C virus (HCV) infection as well as recent efforts to reduce the rate of mother-to-child transmission (MTCT). Maternal infection with either HBV or HCV has been linked to adverse pregnancy and birth outcomes, including MTCT. MTCT for HBV has been reduced to approximately 5% overall in countries including the US that have instituted postpartum neonatal HBV vaccination and immunoprophylaxis with hepatitis B immune globulin. However, the rate of transmission of HBV to newborns is nearly 30% when maternal HBV levels are greater than 200 000 IU ml
−1
(>6 log
10
copies ml
−1
). For these patients, new guidelines from the European Association for the Study of the Liver (EASL) and the Asian Pacific Association for the Study of the Liver (APASL) indicate that, in addition to neonatal vaccination and immunoprophylaxis, treating with antiviral agents such as tenofovir disoproxil fumarate or telbivudine during pregnancy beginning at 32 weeks of gestation is safe and effective in preventing MTCT. In contrast to HBV, no therapeutic agents are yet available or recommended to further decrease the risk of MTCT of HCV, which remains 3 to 10%. HCV MTCT can be minimized by avoiding fetal scalp electrodes and birth trauma whenever possible. Young women with HCV should be referred for treatment post delivery, and neonates should be closely followed to rule out infection. New, better-tolerated treatment regimens for HCV are now available, which should improve outcomes for all infected individuals.</description><identifier>ISSN: 0743-8346</identifier><identifier>EISSN: 1476-5543</identifier><identifier>DOI: 10.1038/jp.2014.167</identifier><identifier>PMID: 25233195</identifier><language>eng</language><publisher>New York: Nature Publishing Group US</publisher><subject>692/699/255/234/2513/1549 ; 692/699/255/234/2513/1551 ; 692/700/478 ; Antigens ; Antiviral agents ; Antiviral Agents - therapeutic use ; Asian Americans ; Birth ; Birth weight ; Breast Feeding ; Care and treatment ; Cesarean Section ; Chemical compounds ; Contraindications ; DNA, Viral - analysis ; Drug abuse ; Female ; Fetuses ; Globulins ; Gynecology ; Health aspects ; Hepatitis ; Hepatitis B ; Hepatitis B virus ; Hepatitis B, Chronic - diagnosis ; Hepatitis B, Chronic - transmission ; Hepatitis C ; Hepatitis C virus ; Hepatitis C, Chronic - diagnosis ; Hepatitis C, Chronic - transmission ; Hospitals ; Humans ; Immunization ; Immunoglobulins ; Immunoprophylaxis ; Infections ; Infectious Disease Transmission, Vertical - prevention & control ; Lamivudine - therapeutic use ; Liver ; Mass Screening ; Medicine ; Medicine & Public Health ; Neonates ; Obstetrics ; Pediatric Surgery ; Pediatrics ; Pharmacology ; Pregnancy ; Pregnancy Complications, Infectious - diagnosis ; Pregnancy Outcome ; Pregnant women ; Premature birth ; Reagents ; Risk factors ; Risk reduction ; Scalp ; state-of-the-art ; Tenofovir ; Thymidine - analogs & derivatives ; Thymidine - therapeutic use ; Trauma ; Vaccination ; Viral infections ; Viremia ; Viruses</subject><ispartof>Journal of perinatology, 2014-12, Vol.34 (12), p.882-891</ispartof><rights>Nature America, Inc. 2014</rights><rights>COPYRIGHT 2014 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Dec 2014</rights><rights>Nature America, Inc. 2014.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c774t-e385174d14980a25ac9d0b1f2435c24993640f2ae85c85cf3d88fd7cfa34dacd3</citedby><cites>FETCH-LOGICAL-c774t-e385174d14980a25ac9d0b1f2435c24993640f2ae85c85cf3d88fd7cfa34dacd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25233195$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dunkelberg, J C</creatorcontrib><creatorcontrib>Berkley, E M F</creatorcontrib><creatorcontrib>Thiel, K W</creatorcontrib><creatorcontrib>Leslie, K K</creatorcontrib><title>Hepatitis B and C in pregnancy: a review and recommendations for care</title><title>Journal of perinatology</title><addtitle>J Perinatol</addtitle><addtitle>J Perinatol</addtitle><description>Our objective was to provide a comprehensive review of the current knowledge regarding pregnancy and hepatitis B virus (HBV) or hepatitis C virus (HCV) infection as well as recent efforts to reduce the rate of mother-to-child transmission (MTCT). Maternal infection with either HBV or HCV has been linked to adverse pregnancy and birth outcomes, including MTCT. MTCT for HBV has been reduced to approximately 5% overall in countries including the US that have instituted postpartum neonatal HBV vaccination and immunoprophylaxis with hepatitis B immune globulin. However, the rate of transmission of HBV to newborns is nearly 30% when maternal HBV levels are greater than 200 000 IU ml
−1
(>6 log
10
copies ml
−1
). For these patients, new guidelines from the European Association for the Study of the Liver (EASL) and the Asian Pacific Association for the Study of the Liver (APASL) indicate that, in addition to neonatal vaccination and immunoprophylaxis, treating with antiviral agents such as tenofovir disoproxil fumarate or telbivudine during pregnancy beginning at 32 weeks of gestation is safe and effective in preventing MTCT. In contrast to HBV, no therapeutic agents are yet available or recommended to further decrease the risk of MTCT of HCV, which remains 3 to 10%. HCV MTCT can be minimized by avoiding fetal scalp electrodes and birth trauma whenever possible. Young women with HCV should be referred for treatment post delivery, and neonates should be closely followed to rule out infection. New, better-tolerated treatment regimens for HCV are now available, which should improve outcomes for all infected individuals.</description><subject>692/699/255/234/2513/1549</subject><subject>692/699/255/234/2513/1551</subject><subject>692/700/478</subject><subject>Antigens</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Asian Americans</subject><subject>Birth</subject><subject>Birth weight</subject><subject>Breast Feeding</subject><subject>Care and treatment</subject><subject>Cesarean Section</subject><subject>Chemical compounds</subject><subject>Contraindications</subject><subject>DNA, Viral - analysis</subject><subject>Drug abuse</subject><subject>Female</subject><subject>Fetuses</subject><subject>Globulins</subject><subject>Gynecology</subject><subject>Health aspects</subject><subject>Hepatitis</subject><subject>Hepatitis B</subject><subject>Hepatitis B virus</subject><subject>Hepatitis B, Chronic - diagnosis</subject><subject>Hepatitis B, Chronic - transmission</subject><subject>Hepatitis C</subject><subject>Hepatitis C virus</subject><subject>Hepatitis C, Chronic - diagnosis</subject><subject>Hepatitis C, Chronic - transmission</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Immunization</subject><subject>Immunoglobulins</subject><subject>Immunoprophylaxis</subject><subject>Infections</subject><subject>Infectious Disease Transmission, Vertical - prevention & control</subject><subject>Lamivudine - therapeutic use</subject><subject>Liver</subject><subject>Mass Screening</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neonates</subject><subject>Obstetrics</subject><subject>Pediatric Surgery</subject><subject>Pediatrics</subject><subject>Pharmacology</subject><subject>Pregnancy</subject><subject>Pregnancy Complications, Infectious - diagnosis</subject><subject>Pregnancy Outcome</subject><subject>Pregnant women</subject><subject>Premature birth</subject><subject>Reagents</subject><subject>Risk factors</subject><subject>Risk reduction</subject><subject>Scalp</subject><subject>state-of-the-art</subject><subject>Tenofovir</subject><subject>Thymidine - analogs & derivatives</subject><subject>Thymidine - therapeutic use</subject><subject>Trauma</subject><subject>Vaccination</subject><subject>Viral infections</subject><subject>Viremia</subject><subject>Viruses</subject><issn>0743-8346</issn><issn>1476-5543</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqNkt1rFDEUxQdR7Fp98l0GBBF01nxNPvog1KVaoeCLPoc0c2c3y0wyJjOV_vdmurXuSpGSgcCc3z3hnnuL4iVGS4yo_LAdlgRhtsRcPCoWmAle1TWjj4sFEoxWkjJ-VDxLaYvQLIqnxRGpCaVY1Yvi7BwGM7rRpfJTaXxTrkrnyyHC2htvr09KU0a4cvDrRoxgQ9-Db3JJ8KlsQyytifC8eNKaLsGL2_u4-PH57PvqvLr49uXr6vSiskKwsQIqayxYg5mSyJDaWNWgS9wSRmtLmFKUM9QSA7K2-WtpI2XbCNsayhpjG3pcfNz5DtNlD40FP0bT6SG63sRrHYzTh4p3G70OV5oJIXIO2eDtrUEMPydIo-5dstB1xkOYks4ZEqQ4F_gBKJeEI8nkA1AiCcOS0oy-_gfdhin6HJomuXlOFeP4f1T2ElwpjMRfam060M63Ifds56f1KVWkFoTVM7W8h8qngd7Z4KF1-f9BwZu9gg2Ybtyk0E03Iz8E3-1AG0NKEdq7QWCk59XU20HPqznHmulX-7O7Y__sYgbe74CUJb-GuNf0PX6_ATCW6AA</recordid><startdate>20141201</startdate><enddate>20141201</enddate><creator>Dunkelberg, J C</creator><creator>Berkley, E M F</creator><creator>Thiel, K W</creator><creator>Leslie, K K</creator><general>Nature Publishing Group US</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>ASE</scope><scope>FPQ</scope><scope>K6X</scope><scope>5PM</scope></search><sort><creationdate>20141201</creationdate><title>Hepatitis B and C in pregnancy: a review and recommendations for care</title><author>Dunkelberg, J C ; Berkley, E M F ; Thiel, K W ; Leslie, K K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c774t-e385174d14980a25ac9d0b1f2435c24993640f2ae85c85cf3d88fd7cfa34dacd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>692/699/255/234/2513/1549</topic><topic>692/699/255/234/2513/1551</topic><topic>692/700/478</topic><topic>Antigens</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Asian Americans</topic><topic>Birth</topic><topic>Birth weight</topic><topic>Breast Feeding</topic><topic>Care and treatment</topic><topic>Cesarean Section</topic><topic>Chemical compounds</topic><topic>Contraindications</topic><topic>DNA, Viral - analysis</topic><topic>Drug abuse</topic><topic>Female</topic><topic>Fetuses</topic><topic>Globulins</topic><topic>Gynecology</topic><topic>Health aspects</topic><topic>Hepatitis</topic><topic>Hepatitis B</topic><topic>Hepatitis B virus</topic><topic>Hepatitis B, Chronic - diagnosis</topic><topic>Hepatitis B, Chronic - transmission</topic><topic>Hepatitis C</topic><topic>Hepatitis C virus</topic><topic>Hepatitis C, Chronic - diagnosis</topic><topic>Hepatitis C, Chronic - transmission</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Immunization</topic><topic>Immunoglobulins</topic><topic>Immunoprophylaxis</topic><topic>Infections</topic><topic>Infectious Disease Transmission, Vertical - prevention & control</topic><topic>Lamivudine - therapeutic use</topic><topic>Liver</topic><topic>Mass Screening</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neonates</topic><topic>Obstetrics</topic><topic>Pediatric Surgery</topic><topic>Pediatrics</topic><topic>Pharmacology</topic><topic>Pregnancy</topic><topic>Pregnancy Complications, Infectious - diagnosis</topic><topic>Pregnancy Outcome</topic><topic>Pregnant women</topic><topic>Premature birth</topic><topic>Reagents</topic><topic>Risk factors</topic><topic>Risk reduction</topic><topic>Scalp</topic><topic>state-of-the-art</topic><topic>Tenofovir</topic><topic>Thymidine - analogs & derivatives</topic><topic>Thymidine - therapeutic use</topic><topic>Trauma</topic><topic>Vaccination</topic><topic>Viral infections</topic><topic>Viremia</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dunkelberg, J C</creatorcontrib><creatorcontrib>Berkley, E M F</creatorcontrib><creatorcontrib>Thiel, K W</creatorcontrib><creatorcontrib>Leslie, K K</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>British Nursing Index</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>British Nursing Index</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of perinatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dunkelberg, J C</au><au>Berkley, E M F</au><au>Thiel, K W</au><au>Leslie, K K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hepatitis B and C in pregnancy: a review and recommendations for care</atitle><jtitle>Journal of perinatology</jtitle><stitle>J Perinatol</stitle><addtitle>J Perinatol</addtitle><date>2014-12-01</date><risdate>2014</risdate><volume>34</volume><issue>12</issue><spage>882</spage><epage>891</epage><pages>882-891</pages><issn>0743-8346</issn><eissn>1476-5543</eissn><abstract>Our objective was to provide a comprehensive review of the current knowledge regarding pregnancy and hepatitis B virus (HBV) or hepatitis C virus (HCV) infection as well as recent efforts to reduce the rate of mother-to-child transmission (MTCT). Maternal infection with either HBV or HCV has been linked to adverse pregnancy and birth outcomes, including MTCT. MTCT for HBV has been reduced to approximately 5% overall in countries including the US that have instituted postpartum neonatal HBV vaccination and immunoprophylaxis with hepatitis B immune globulin. However, the rate of transmission of HBV to newborns is nearly 30% when maternal HBV levels are greater than 200 000 IU ml
−1
(>6 log
10
copies ml
−1
). For these patients, new guidelines from the European Association for the Study of the Liver (EASL) and the Asian Pacific Association for the Study of the Liver (APASL) indicate that, in addition to neonatal vaccination and immunoprophylaxis, treating with antiviral agents such as tenofovir disoproxil fumarate or telbivudine during pregnancy beginning at 32 weeks of gestation is safe and effective in preventing MTCT. In contrast to HBV, no therapeutic agents are yet available or recommended to further decrease the risk of MTCT of HCV, which remains 3 to 10%. HCV MTCT can be minimized by avoiding fetal scalp electrodes and birth trauma whenever possible. Young women with HCV should be referred for treatment post delivery, and neonates should be closely followed to rule out infection. New, better-tolerated treatment regimens for HCV are now available, which should improve outcomes for all infected individuals.</abstract><cop>New York</cop><pub>Nature Publishing Group US</pub><pmid>25233195</pmid><doi>10.1038/jp.2014.167</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0743-8346 |
| ispartof | Journal of perinatology, 2014-12, Vol.34 (12), p.882-891 |
| issn | 0743-8346 1476-5543 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4777346 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | 692/699/255/234/2513/1549 692/699/255/234/2513/1551 692/700/478 Antigens Antiviral agents Antiviral Agents - therapeutic use Asian Americans Birth Birth weight Breast Feeding Care and treatment Cesarean Section Chemical compounds Contraindications DNA, Viral - analysis Drug abuse Female Fetuses Globulins Gynecology Health aspects Hepatitis Hepatitis B Hepatitis B virus Hepatitis B, Chronic - diagnosis Hepatitis B, Chronic - transmission Hepatitis C Hepatitis C virus Hepatitis C, Chronic - diagnosis Hepatitis C, Chronic - transmission Hospitals Humans Immunization Immunoglobulins Immunoprophylaxis Infections Infectious Disease Transmission, Vertical - prevention & control Lamivudine - therapeutic use Liver Mass Screening Medicine Medicine & Public Health Neonates Obstetrics Pediatric Surgery Pediatrics Pharmacology Pregnancy Pregnancy Complications, Infectious - diagnosis Pregnancy Outcome Pregnant women Premature birth Reagents Risk factors Risk reduction Scalp state-of-the-art Tenofovir Thymidine - analogs & derivatives Thymidine - therapeutic use Trauma Vaccination Viral infections Viremia Viruses |
| title | Hepatitis B and C in pregnancy: a review and recommendations for care |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T15%3A36%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hepatitis%20B%20and%20C%20in%20pregnancy:%20a%20review%20and%20recommendations%20for%20care&rft.jtitle=Journal%20of%20perinatology&rft.au=Dunkelberg,%20J%20C&rft.date=2014-12-01&rft.volume=34&rft.issue=12&rft.spage=882&rft.epage=891&rft.pages=882-891&rft.issn=0743-8346&rft.eissn=1476-5543&rft_id=info:doi/10.1038/jp.2014.167&rft_dat=%3Cgale_pubme%3EA392572457%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1627699107&rft_id=info:pmid/25233195&rft_galeid=A392572457&rfr_iscdi=true |